ID | 1077 |
Name of the vaccine | Decavac |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 7 years and older |
Description of the vaccine | Tetanus and Diphtheria Toxoids Adsorbed (Td vaccine). |
Name of the manufacturer | Sanofi Pasteur Inc. |
Name of the manufacturing country | United States |
Year of manufacture | 1955 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | NA |
Vaccine formulation | Sterile suspension |
Dosage | Primary Immunization - three 0.5 mL doses.
Routine booster - in children 11-12 years of age and every 10 years. |
Mechanism of action | Serum tetanus antitoxin level-
0.01 IU/mL - lowest protection level.
Greater than or equal 0.1 IU/mL - Protective |
Route of administration | Intramuscular |
Indications | Active immunization for the prevention of tetanus and diphtheria. |
Export | NA |
Approval | US FDA |
Adjuvant | Alum |
Repurposing | For diphtheria also. |
Side effects of vaccine | Pain, headache, injection site swelling and erythema, muscle weakness, tiredness, diarrhoea, chills, nausea, sore and swollen joints. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.vaccineshoppe.com/assets/pdf/decavac.pdf |
Other name | NA |
Additional Links | NA
|